American Academy of Allergy Asthma and Immunology/World Allergy Organization Joint Congress (AAAAI/WAO Joint Congress 2025)

San Diego, California, US 28 February 2025 - 03 March 2025

Dupilumab eases itch, disease activity in chronic spontaneous urticaria

16 Jun 2025 by

Patients with chronic spontaneous urticaria (CSA) who has uncontrolled disease despite treatment with H1-antihistamines may benefit from using dupilumab, which has been shown to reduce itch and urticaria activity in two phase III trials.

Dupilumab eases itch, disease activity in chronic spontaneous urticaria

16 Jun 2025

Lebrikizumab improves anxiety, depression symptoms in adolescents with AD

18 Mar 2025 by

Lebrikizumab improves anxiety and depression symptoms, as shown by PROMIS* scores, in patients with moderate-to-severe atopic dermatitis (AD), according to the ADore trial presented at AAAAI/WAO 2025.

Lebrikizumab improves anxiety, depression symptoms in adolescents with AD

18 Mar 2025

Sublingual film a reliable lifeline for life-threatening allergic reactions?

17 Mar 2025 by

Data presented at AAAAI/WAO 2025 verify the potential of the epinephrine sublingual film (ESF) Anaphylm for the treatment of type 1 allergic reactions, including anaphylaxis.

Sublingual film a reliable lifeline for life-threatening allergic reactions?

17 Mar 2025

Children with food allergies at risk of stunting, but immunotherapy helps

16 Mar 2025 by

Eliminating certain foods such as egg and milk from children’s diet due to IgE-mediated allergy may hinder growth, but oral immunotherapy helps improve growth trajectories, especially when initiated at a younger age, according to two studies.

Children with food allergies at risk of stunting, but immunotherapy helps

16 Mar 2025

Could early formula feeding be promoting infant food allergies?

15 Mar 2025 by

Newborns who are not exclusively fed colostrum within the first 3 days of life may have a higher likelihood of developing food allergies, according to a study.

Could early formula feeding be promoting infant food allergies?

15 Mar 2025

Ruxolitinib cream shows benefit in patients with AD, regardless of age

15 Mar 2025 by

Twice-daily application of ruxolitinib cream monotherapy appears effective and well tolerated in the treatment of mild-to-moderate atopic dermatitis (AD), regardless of age, based on a pooled analysis of three phase III trials presented at AAAAI/WAO 2025.

Ruxolitinib cream shows benefit in patients with AD, regardless of age

15 Mar 2025

Twice-yearly depemokimab safe, effective in CRSwNP

14 Mar 2025 by

Treatment with two doses of depemokimab results in sufficient concentrations to adequately control blood eosinophil counts (BEC) over 1 year, as shown in the ANCHOR 1 and 2 trials. This finding suggests sustained anti-interleukin-5 (IL-5) biological effect and impact on type 2 inflammation.

Twice-yearly depemokimab safe, effective in CRSwNP

14 Mar 2025

Omalizumab continues to OUtMATCH OIT in updated analysis

14 Mar 2025 by

Omalizumab remains superior to oral immunotherapy (OIT) for the treatment of multi-food allergies with fewer adverse effects in Stage 2 of the NIH*-sponsored phase III OUtMATCH** study, the first head-to-head trial comparing the two treatments.

Omalizumab continues to OUtMATCH OIT in updated analysis

14 Mar 2025

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

07 Mar 2025 by

The attainment of remission in EGPA is durable whether treated with benralizumab for 2 years or switched to benralizumab after 52 weeks of mepolizumab treatment, with additional merits observed among those who switched, as indicated in the OLE of MANDARA

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

07 Mar 2025